Rotigotine: Transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 285-295

  Splinter, Michele Y ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Dopamine agonist; Rotigotine

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

ADD ON THERAPY; ANOREXIA; ANXIETY; APPLICATION SITE REACTION; BLISTER; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MEDLINE; MENTAL DISEASE; MONOTHERAPY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYPHYLAXIS; VIVID DREAM; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 33847396972     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H113     Document Type: Review

References (44)

1. Rascol O. Transdermal delivery of dopaminergic agents. Neurology 2005;65(suppl 1):S1-2.
2. SchwarzPharma. Neupro approved in Europe for early Parkinson's disease. www.schwarzpharma.com/?node_id=2492 (accessed 2006 May 19).
3. SchwarzPharma. Neupro receives approvable letter from FDA for early Parkinson's disease in USA. www.schwarzpharma.com/?node_id=2494 (accessed 2006 May 19).
4. SchwarzPharma. Schwarz Pharma's Parkinson patch offers additional benefits. www.schwarzpharma.com/?action=show_content&print=1&node_id= 2546 (accessed 2006 Sept 12).
5. Nugroho AK, Li G, Grossklaus A, Danhof M, Bouwstra JA. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J Control Release 2004;96:159-67.
6. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005;4:465-75.
7. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(suppl 1):1-9.
8. Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 2005;65(suppl 1):S11-4.
9. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
10. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):S1-88.
11. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91.
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8.
13. Garcia Ruiz PJ, Meseguer E, Del Val J, Vazquez A, Sanchez Bernardos V, Vazquez A. Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 2004;27:49-52.
14. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-6.
15. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-81.
16. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-6.
17. Happe S, Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004;18:27-36.
18. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.
19. Mucke HA. Rotigotine Schwarz Pharma. IDrugs 2003;6:894-9.
20. Quinn N. For the European and South African Rotigotine CDS Study Group. A multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of rotigotine constant delivery system (CDS) in patients with advanced Parkinson's disease (poster A223). Presented at: XIV International Congress on Parkinson's Disease, Helsinki, July 28-August 1, 2001.
21. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65(suppl 1):S3-5.
22. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006;527-45.
23. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-7.
24. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006;297-315.
25. Westfall TC, Westfall DP. Neurotransmission. The autonomic and somatic motor nervous systems. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006;137-81.
26. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8.
27. Braun M, Cawello W, Poole K, Hortsmann R. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease (poster P1245). Presented at: 9th Congress of the European Federation of Neurological Societies, Athens, September 17-20, 2005.
28. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001;24:163-9.
29. Watts RL, Wendt J, Nausieda PA, Poole KH, Sommerville KW, Boroojerdi B. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease. A multicenter, multinational, randomized, double-blind, placebo-controlled trial (abstract P737 and poster). Mov Disord 2004;19(suppl 9):S258. Presented at: 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, June 14-17, 2004.
30. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function (abstract). J Clin Pharmacol 2005;45:1091.
31. Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005;28:106-10.
32. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine (abstract 101). J Clin Pharmacol 2005;45:1091.
33. Watts RL, LeWitt PA, Giladi N, Sommerville KW, Boroojerdi B. Treatment with rotigotine transdermal system may attenuate progression of disability in patients with early-stage Parkinson's disease (abstract P02.103). Neurology 2005;64(suppl 1):A107.
34. Watts RL, Pahwa R, Lyons K, Boroojerdi B, Wallen LM. Long-term safety and efficacy of the rotigotine transdermal patch in early-stage Parkinson's disease (poster P05.136). Presented at: 58th Annual Meeting of the American Academy of Neurology, San Diego, CA, April 6, 2006.
35. 2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001;16:459-63.
36. LeWitt PA, Chang F-L, Fazzini E, Nausieda P, Daniel T, Boroojerdi B. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease (abstract no. SC115). Presented at: 9th Congress of the European Federation of Neurological Societies, Athens, September 17-20, 2005.
37. Giladi N, Tolosa E, Boothman B, et al. Rotigotine transdermal system in patients with idiopathic Parkinson's disease: results of two placebo- and comparator-controlled trials (poster). Presented at: First World Parkinson's Congress, Washington, DC, February 21-26, 2006.
38. Poewe W, Giladi N, Boothman B, Maguire D, Boroojerdi B. For SP515 Study Group. Rotigotine transdermal system in patients with advanced-stage Parkinson's disease as adjunctive therapy to levodopa: results of a placebo- and pramipexole-controlled trial. Presented at: First World Parkinson's Congress, Washington, DC, February 21-26, 2006.
39. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 2005;20(suppl 11):S30-7.
40. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D. The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 1999;22:207-12.
41. Patton J, Neilson S, Boroojerdi B. Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease (poster). Presented at: First World Parkinson's Congress, Washington, DC, February 21-26, 2006.
42. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH: Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-8.
43. Stiasny-Kolster K, Garcia-Borreguero D, Saletu B, Schollmayer E, Kohnen R, Oertel WH; SP709 Study Group. Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome-a double-blind placebo-controlled multi-center dose-finding study (poster). Presented at: 9th Congress of the European Federation of Neurological Societies, Athens, September 17-20, 2005.
44. Babic T, Boroojerdi B, Randerath O, Poole K, Sommerville KW. Rotigotine CDS patch in advanced-stage, idiopathic Parkinson's disease: a parallel group, open-label, dose-escalation trial (poster). Presented at: 56th Annual Meeting of the American Academy of Neurology, San Francisco, April 27-May 1, 2004.